The CZT Dynamic Myocardial Perfusion Imaging

The Quantification, Clinical Application of Dynamic Imaging Using Cadmium-zinc-telluride (CZT) Cameras to Assess Myocardial Perfusion

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02697760

Acronym

CZT

Enrollment

234

Registered

2016-03-03

Start date

2015-09-30

Completion date

2022-10-31

Last updated

2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease

Keywords

cadmium-zinc-telluride，CZT cameras, myocardial blood flow，MBF, myocardial flow reserve，MFR

Brief summary

To develop and validate the noninvasive measurement of MBF and MFR by using dynamic imaging with a CZT camera, and evaluate the diagnostic and prognostic implications in various heart disease.

Detailed description

Absolute myocardial blood flow (MBF) and myocardial flow reserve (MFR) provide incremental diagnostic and prognostic information over relative perfusion alone. Recent development of dedicated cardiac SPECT cameras with better sensitivity and temporal resolution make dynamic SPECT imaging more practical. The potential roles of myocardial perfusion in subjects with cardiovascular risks and heart failure warrant further investigations. The present project aims to develop and validate the noninvasive measurement of MBF and MFR by using dynamic imaging with a CZT camera, and evaluate the diagnostic and prognostic implications.

Interventions

RADIATIONthallium-201

Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Coronary heart disease 2. Clinical diagnosis of heart failure 3. Clinical diagnosis of metabolic diseases (such as metabolic syndrome, obesity, diabetes, hyperlipidemia, micro vascular diseases, etc.), heart failure or coronary heart disease in high-risk groups persons.

Exclusion criteria

Significant systemic disease (except heart disease) such as cirrhosis, end-stage renal disease or active malignancy, estimated life expectancy of less than three months, persons; pregnant or lactating women have the possibility of pregnancy.

Design outcomes

Primary

Measure	Time frame	Description
Coronary artery disease (CAD) diagnosis	12 months after the index MPI	CAD defined as more than 50% stenosis in any vessel by coronary angiography or computed tomography.

Secondary

Measure	Time frame	Description
MACE (major adverse cardiac events)	5 years after the index MPI	revascularization, acute myocardial infarction, hospitalization for heart failure, cardiac death, non-cardiac death

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026